The firm is an early-stage venture capital firm that primarily invests at the Seed and Series A stages, often serving as the first institutional investor in its portfolio companies. Initial investments typically range from approximately $500K to $7M, with the capacity to invest $15M or more over the life of a company. The firm invests globally but maintains a strong focus on opportunities emerging from major innovation hubs in the United States. The firm follows a thesis-driven investment strategy centered on building category-defining companies addressing large, underserved markets.  

Within healthcare, the firm invests in medical technology, medical devices, diagnostics, genomics-enabled diagnostics, bioinformatics platforms, laboratory services, and other data-driven healthcare businesses. The firm seeks disruptive technologies capable of transforming large clinical markets, with particular interest in opportunities addressing diabetes, cardiovascular disease, hypertension, obesity, and other significant unmet healthcare needs. The firm emphasizes scalable business models, differentiated innovation, and the potential to create or redefine large markets.  

From a company and management team perspective, the firm frequently serves as the lead or co-lead investor and takes an active board role. The firm works closely with portfolio companies on strategy, executive recruitment, product development, commercialization, and fundraising. While experienced leadership teams are valued, the firm is also willing to back first-time founders who demonstrate exceptional vision, technical expertise, and the ability to execute against large market opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an international venture capital firm focused on investing in clinical-stage healthcare companies. The firm invests primarily in companies advancing therapeutic programs while also considering opportunities in diagnostics, medical devices, and digital health. The firm generally targets companies conducting Phase I or Phase II clinical trials or equivalent stages of development and invests across major healthcare markets.  

The firm’s primary focus is therapeutics, although it remains open to diagnostics, medical devices, and digital health opportunities. The firm is generally indication-agnostic but has particular interest in diabetes, pulmonology, ophthalmology, oncology, and other areas with significant unmet medical need. The firm prioritizes companies with meaningful clinical validation and strong translational potential.  

From a company and management team perspective, the firm typically participates as a co-investor and generally prefers opportunities that already have a lead investor in place. The firm does not typically require board representation and does not have specific management team requirements, allowing it to work with a broad range of experienced and emerging leadership teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a European venture capital firm focused on early-stage technology and healthcare investments. The firm primarily invests at the Seed and Series A stages, with selective participation in Series B financings and significant follow-on capacity. Initial investments typically range from approximately €500K to €3M, with total commitments of up to €10M–15M per portfolio company. The firm has established a dedicated healthcare investment platform supported by strategic partners across the healthcare ecosystem and primarily invests in companies across Europe.  

The firm focuses primarily on digital health, including health data platforms, diagnostics, care delivery technologies, clinical workflow solutions, and other enabling healthcare technologies. The firm also selectively invests in medical technology companies, particularly those incorporating connected care, artificial intelligence, or digital components. The firm seeks businesses with differentiated technologies capable of improving clinical outcomes or healthcare system efficiency.  

From a company and management team perspective, the firm is an active investor that frequently serves as lead investor and consistently takes a board seat. The firm works closely with portfolio companies on corporate strategy, financing, talent recruitment, business development, and strategic partnerships, providing hands-on operational support throughout the company’s growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture capital arm of a global pharmaceutical company invests in innovative digital health companies worldwide. Established in 2015, the firm supports companies from Seed through later-stage venture financings and can invest up to approximately $5M per financing round. The firm seeks strategic investments that complement its parent company’s long-term healthcare priorities while helping portfolio companies accelerate product development and commercial adoption. 

The firm focuses exclusively on digital health, with particular interest in prevention and medication adherence technologies, digital therapeutics, digital medical devices, and big data analytics platforms. Key areas of interest include chronic diseases such as diabetes, obesity, and cardiovascular disease, as well as respiratory diseases, oncology, consumer health, and mental health. The firm seeks innovative technologies that improve patient outcomes through connected care, data-driven insights, and digital healthcare solutions. 

From a company and management team perspective, the firm prefers experienced leadership teams with demonstrated expertise in their respective markets and well-developed business plans. The firm partners with companies globally and seeks management teams capable of successfully commercializing innovative digital health technologies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The U.S.-based research and business development arm of a global pharmaceutical company serves as its international innovation and partnering platform. Rather than operating as a traditional venture capital investor, the firm identifies and evaluates external innovation to strengthen the parent company’s research and development pipeline. The firm collaborates with biotechnology and pharmaceutical companies worldwide through strategic partnerships, in-licensing, co-development, and other business development transactions to accelerate the advancement of innovative medicines. The firm focuses on therapeutic innovation across anti-infectives, central nervous system disorders, oncology, autoimmune diseases, and metabolic diseases.  

The firm is open to a broad range of therapeutic modalities and actively seeks novel drug candidates, platform technologies, and translational research programs that align with its strategic development priorities. The firm evaluates opportunities across preclinical and clinical development and pursues flexible partnership structures tailored to the needs of each program.  

From a company and management team perspective, the firm seeks partners with differentiated science, strong intellectual property, and compelling preclinical or clinical data supporting global development potential. The firm values companies with well-defined development strategies and innovative assets that can address significant unmet medical needs. Through its global development, regulatory, manufacturing, and commercialization capabilities, the firm works closely with partners to advance promising therapies toward international markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a healthcare-focused venture capital firm based in the United States that invests in novel, differentiated therapeutics addressing significant unmet medical needs. The firm makes direct equity investments across the full development spectrum, from preclinical programs through clinical- and commercial-stage companies. The firm participates in Seed and first institutional rounds, later-stage private financings, crossover rounds, and PIPE transactions, with the capacity to invest up to approximately $15M over the life of an investment. The firm can act as a lead, co-lead, or co-investor and invests in both private and public companies.  

The firm focuses primarily on therapeutics in oncology, immunology, neurology, and rare diseases, while remaining open to other indications on a selective basis. The firm is stage-agnostic and prioritizes differentiated science, strong biological rationale, and programs with meaningful clinical and commercial potential. The firm seeks opportunities capable of addressing substantial unmet needs and reaching important development, regulatory, or commercial value-inflection milestones.  

From a company and management team perspective, the firm prefers experienced leadership teams with strong scientific and drug development expertise. The firm partners closely with scientists, entrepreneurs, and institutional co-investors and provides strategic support through its pharmaceutical and healthcare industry network. The firm seeks to help portfolio companies advance toward clinical milestones, strategic partnerships, follow-on financings, and successful exits.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.